Drug intelligence / Profile preview

lexanopadol

Development stage: Unknown
Lead developer: Grünenthal
Modality: Small Molecules
Administration: Oral

Overview

Lexanopadol (GRT6006) is an investigational small molecule analgesic being developed by Grünenthal for the treatment of moderate to severe chronic pain, including neuropathic pain. It acts as a dual agonist at the nociceptin/orphanin FQ (NOP) receptor (also known as the opioid receptor-like 1 or ORL-1 receptor) and the mu-opioid receptor (MOR). This dual mechanism of action is intended to provide potent analgesia with a potentially improved safety profile, specifically reduced risk of respiratory depression and physical dependence compared to traditional mu-opioid agonists. Lexanopadol has undergone Phase 1 clinical evaluation, including studies to characterize its metabolic profile and excretion balance in healthy volunteers.

Other names: lexanopadol

Targets

NOP (Nociceptin/orphanin FQ peptide receptor)

Beyond the preview

Go deeper on lexanopadol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lexanopadol.

Explore the full profile